Floatz logo

Valganciclovir

Cytomegalovirus Infection

The Methodist Hospital Research InstituteSmall moleculePhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Cytomegalovirus Infection cohort.

Asset / SponsorPhaseRating
Foscarnet
City of Hope Medical Center
Phase 4BB
Ganciclovir
City of Hope Medical Center
Phase 3BB
Letermovir
Fernanda P Silveira, MD, MS
Phase 2B
Cmvpp65-A*0201 Peptide Vaccine
City of Hope Medical Center
Phase 2B
Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine
City of Hope Medical Center
Phase 2CCC

View all 16 →

Same molecule, other indications

Valganciclovir is also rated in:

lymphoproliferative syndromeDormant
B
Indicative ·
61 / 100
View asset →
Epstein-Barr virus-associated lymphoproliferative disorderDormant
B
Indicative ·
61 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →